엑세스바이오

950130KOSDAQ

47.0 / 100

Reference Date: 2026-10-23

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 21.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AccessBio develops and sells diagnostic products based on in-vitro diagnostics (IVD) technologies, focusing on infectious disease rapid diagnostic tests (RDTs) for malaria, influenza, and COVID-19. Its COVID-19 diagnostic products, which received FDA Emergency Use Authorization, have become a major revenue driver, with the company expanding globally amid growing IVD market demand.

Number of Employees

75people

Average Salary

159.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-14.02Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.40Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼71.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼727.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.0% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,936Won52-week high 4,40052-week low 1,936

1-month return0.0Point

1m -20.98% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 1Neutral 0Negative 0

Positive단일판매ㆍ공급계약체결2026-10-20